Each MEN subtype arises from heritable pathogenic variants in distinct causative genes; specific gene assignments per subtype are not comprehensively enumerated in the known_genes field of this packet, which reflects the multi-subtype, parent-group nature of the MONDO entry. For MEN1, GeneReviews documents autosomal dominant inheritance, in which a single pathogenic variant copy is sufficient to confer predisposition to tumor development. Approximately 90% of individuals with MEN1 have an affected parent; approximately 10% carry a variant that arose de novo in early embryogenesis. GeneReviews notes that no direct genotype-phenotype correlations have been identified in MEN1—the specific variant does not reliably predict which tumors will develop or their severity. The penetrance data, inheritance pattern, and molecular characteristics described here are derived from GeneReviews documentation of MEN1 and do not extend to the full MEN group, which encompasses molecularly distinct subtypes.

Diagnosis within the MEN syndromes depends on the specific subtype and the clinical context in which endocrine tumors are identified. For MEN1, GeneReviews documents that the diagnosis is suspected in individuals who develop endocrine tumors, though non-endocrine manifestations may precede hormone-secreting tumor development. Parathyroid tumors are identified through biochemical detection of hypercalcemia resulting from excess parathyroid hormone production; GeneReviews notes that imaging is not required for diagnosis when biochemical evidence of primary hyperparathyroidism is present. GeneReviews also notes that no single clinical criterion or definition captures all affected individuals with MEN1, given the variability of tumor combinations that may occur. Molecular genetic testing for causative variants in the relevant gene for each MEN subtype plays a central role in confirming the diagnosis and enabling systematic evaluation of family members.

No FDA-approved treatments specific to the MEN group as a whole are documented in this packet's approved treatments field. Management is subtype- and manifestation-specific. For MEN1, GeneReviews describes surgical intervention as the established approach for primary hyperparathyroidism: parathyroidectomy addresses the overactive parathyroid glands, though the extent of surgery—subtotal (removal of up to 3.5 glands) versus total parathyroidectomy—remains a subject of ongoing clinical discussion, with documented rates of persistent or recurrent hypercalcemia within 10–12 years following subtotal resection. Pancreatic and duodenal neuroendocrine tumors in MEN1 are addressed through surgical and pharmacologic approaches appropriate to each tumor's secretory profile and size. Pituitary tumor management varies by tumor subtype. Clinical practice guidelines for MEN1 management have been developed, as documented in GeneReviews, encompassing both treatment of identified manifestations and prospective surveillance in individuals with relevant pathogenic variants. Investigational therapeutic research includes anti-VEGF-A monoclonal antibody approaches studied in early-stage animal models for MEN1-associated pituitary prolactinomas, as documented in GeneReviews.

Prognosis across the MEN syndromes is shaped by which tumors develop, their malignant potential, and the effectiveness of detection and intervention. For MEN1, GeneReviews documents that surveillance can detect disease onset approximately 10 years before clinical symptoms emerge, providing a window for earlier intervention. The high age-related penetrance of MEN1, exceeding 95% by age 40, means that disease features typically accumulate across adulthood. Certain MEN1-associated tumors, including some pancreatic and thymic neuroendocrine tumors, carry malignant potential. GeneReviews notes that early detection and treatment are expected to reduce the morbidity and mortality associated with MEN1. Prognosis for MEN2 and MEN4 depends on subtype-specific tumor trajectories and is not detailed in this packet.

The MEN syndromes are an active area of clinical investigation. This packet documents 17 active clinical trials. Among the detailed trials, NCT04969926 is an NIH/NIDDK-sponsored natural history study of parathyroid disorders (recruiting, estimated completion 2031). NCT07444723 is a Phase 2 trial evaluating 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT imaging for localization of parathyroid tumors, also NIDDK-sponsored (recruiting, initiated April 2026). NCT05037461 is investigating precision radiotherapy using an MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (recruiting). Long-running registries contribute to natural history characterization, including NCT03048279 (the M.D. Anderson Cancer Center MEN1/MEN2 registry, active not recruiting) and the Sanford Health Rare Disease Registry (NCT01793168). NCT06790251 is establishing an Italian multicenter database of MEN1 patients (not yet recruiting as of packet date). Intervention types represented across the trial landscape include drug therapy, medical devices, and procedural interventions. The published research literature for MEN encompasses 199 classified publications in this packet, with reviews and meta-analyses as the dominant publication type; biomarker-focused and gene therapy-related publications are also documented.